CASC3 and Miyoshi myopathy: BTZ is a first-generation PI that binds the 20S proteasome and approved in 2003 to treat refractory multiple myeloma (MM) in adults and is currently FDA approved for adult use in de novo and relapsed/refractory MM and relapsed/refractory mantle cell lymphoma (Raedler, 2015).